Cabaletta Bio is trading 5.5% down at $2.75, pressured by a broader selloff tied to hotter-than-expected wholesale inflation.

  • The decline extends after September 9’s 11.01% drop.
  • No new negative company-specific announcement was identified; recent conference coverage highlighted positive rese-cel safety and manufacturing updates, with more than 90 patients dosed without IEC-HS cases.
  • Rising Treasury yields and Brent crude above $100 amid U.S.-Iran tensions also weighed on broader markets.